Patents by Inventor Darshan Parekh

Darshan Parekh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230226147
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 20, 2023
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Patent number: 11559561
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: January 24, 2023
    Assignee: TRANSLATE BIO, INC.
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Publication number: 20220087935
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: January 7, 2020
    Publication date: March 24, 2022
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Publication number: 20210187122
    Abstract: The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.
    Type: Application
    Filed: September 10, 2020
    Publication date: June 24, 2021
    Inventors: Michael Heartlein, Frank DeRosa, Jonathan Cherry, Paula Lewis, Shrirang Karve, Zarna Patel, Darshan Parekh, Susan Wood, Chi-Sung Chiu, Caroline J. Woo
  • Patent number: 10780183
    Abstract: The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 22, 2020
    Assignee: TRANSLATE BIO, INC.
    Inventors: Michael Heartlein, Frank DeRosa, Jonathan Cherry, Paula Lewis, Shrirang Karve, Zarna Patel, Darshan Parekh, Susan Wood, Chi-Sung Chiu, Caroline J. Woo
  • Publication number: 20200215157
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 9, 2020
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Publication number: 20180369413
    Abstract: The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.
    Type: Application
    Filed: June 19, 2018
    Publication date: December 27, 2018
    Inventors: Michael Heartlein, Frank DeRosa, Jonathan Cherry, Paula Lewis, Shrirang Karve, Zarna Patel, Darshan Parekh, Susan Wood, Chi-Sung Chiu, Caroline J. Woo
  • Bag
    Patent number: D1021384
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: April 9, 2024
    Assignee: Color Maple Ltd.
    Inventor: Darshan Parekh